FPCG
ELDN icon

Forum Private Client Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Forum Private Client Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.8K Hold
10,000
– – 0.01% 80
2025
Q4 		$15.1K Buy
+10,000
New +$23.8K 0.01% 81

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Forum Private Client Group's ELDN Position: Q1 2026 in Review

Forum Private Client Group held its Eledon Pharmaceuticals (ELDN) position steady in Q1 2026 at 10,000 shares worth $30.8K. The position accounts for 0.01% of the portfolio, ranked #80.

Forum Private Client Group first reported a position in ELDN in Q4 2025 and has held it in 2 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Forum Private Client Group held 10,000 shares of Eledon Pharmaceuticals worth $30.8K as of Q1 2026.
  • Forum Private Client Group left its Eledon Pharmaceuticals share count unchanged in Q1 2026.
  • Eledon Pharmaceuticals made up 0.01% of Forum Private Client Group's portfolio in Q1 2026, its #80 holding.
  • Forum Private Client Group first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Forum Private Client Group's 13F filing for Q1 2026, filed 13 May 2026.